Skip to main content
Home
Latest news
Browse topics
Cardiovascular disorders Chronic kidney disease Diabetes devices & technology GLP-1 receptor agonists Hyperglycemia Hypoglycemia Obesity, diet, & lifestyle interventions SGLT2 inhibitors Type 1 diabetes Type 2 diabetes Browse all topics
EN
EN
In focus
Novel clinical evidence in continuous glucose monitoring Fasting for religion and health in people with diabetes The challenge of type 2 diabetes in children HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved Addressing suicide risk in diabetes: Rates and risk factors, HCP fears, and practical advice The SURPASS trials: Summarizing efficacy data on tirzepatide Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials Why psychosocial care matters DiRECT: Type 2 diabetes remission through weight management
Congress coverage
EASD 58th Annual Meeting 2022 The American Diabetes Association 82nd Scientific Sessions
About us
Medicine Matters Diabetes
EXTENDED SEARCH

More on GLP-1 receptor agonists

More on GLP-1 receptor agonists

08-31-2023 | Type 2 diabetes | News

Pragmatic trial suggests best cardioprotective agents for type 2 diabetes

07-20-2023 | Type 2 diabetes | News

Triple agonist shows promise for both glycemic and weight control

07-14-2023 | Type 2 diabetes | News

Cagrilintide plus semaglutide shows dual benefit in type 2 diabetes

06-05-2023 | Prediabetes | News

Caloric restriction outperforms liraglutide for weight loss in prediabetes

03-10-2023 | Primary care | News

COORDINATEd intervention boosts optimal prescribing in type 2 diabetes with ASCVD

02-08-2023 | Heart failure | News

Meta-analysis shows mixed picture for GLP-1 receptor agonists in heart failure

01-09-2023 | Semaglutide | News

FDA approves high-dose semaglutide for adolescents with obesity

12-01-2022 | Semaglutide | News

High-dose semaglutide reduces obesity-linked inflammatory marker

11-22-2022 | Dulaglutide | News

FDA clears dulaglutide for adolescents

11-02-2022 | Semaglutide | News

STEP TEENS: High-dose semaglutide weight loss benefits shown in adolescents

11-01-2022 | Medications | News

Triple agonist shows early promise for type 2 diabetes

11-01-2022 | SGLT2 inhibitors | News

Real-world adjunctive medication outcomes in type 1 diabetes revealed

10-24-2022 | Cardiovascular outcomes | News

Meta-analysis may guide optimal type 2 diabetes glucose-lowering agent for MACE protection

10-10-2022 | Semaglutide | News

STEP 5: Sustained semaglutide treatment maintains weight loss

10-04-2022 | Healthcare costs | News

First-line SGLT2 inhibitors, GLP-1 receptor agonists ‘not cost effective’

09-12-2022 | GLP-1 agonists | Ask the expert | Article

Initiating GLP-1 receptor agonists: Managing side effects

09-01-2022 | Metformin | News

People with type 2 diabetes and CKD missing out on renoprotective drugs

08-25-2022 | Physical activity | News

Initiating glucose-lowering therapy may be linked to a reduction in physical activity

07-05-2022 | Heart failure | News

Highest CV risk may warrant SGLT2 inhibitor rather than GLP-1 receptor agonist

06-04-2022 | ADA 2022 | Conference coverage | News

AWARD-PEDS: Dulaglutide improves glycemic control for youths with type 2 diabetes
Next